We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

60 hedge funds and large institutions have $173M invested in Xenon Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

0.73% less ownership

Funds ownership: 68.88% → 68.15% (-0.73%)

4% less capital invested

Capital invested by funds: $180M → $173M (-$7.03M)

5% less funds holding

Funds holding: 63 → 60 (-3)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
60
Holders Change
-3
Holders Change %
-4.76%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
8
Increased
18
Reduced
13
Closed
10
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$9K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$6.25M
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$2.18M
3
NMC
NEA Management Company
Maryland
+$1.75M
4
ACP
Acuta Capital Partners
California
+$1.43M
5
Russell Investments Group
Russell Investments Group
United Kingdom
+$753K

Top Sellers

1
SFM
Sphera Funds Management
Israel
-$5.42M
2
SSA
Schonfeld Strategic Advisors
New York
-$5.08M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.05M
4
SCM
Stonepine Capital Management
Oregon
-$1M
5
IPC
Invesco Private Capital
New York
-$808K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$917K +$582K +60,863 +189%
Russell Investments Group
27
Russell Investments Group
United Kingdom
$821K +$753K +78,679 +1,710%
SC
28
Scotia Capital
Ontario, Canada
$660K -$1.39K -145 -0.2%
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$595K +$31.6K +3,302 +6%
California Public Employees Retirement System
30
California Public Employees Retirement System
California
$553K +$10.6K +1,105 +2%
AA
31
ALPS Advisors
Colorado
$531K -$67.7K -7,076 -12%
BFM
32
Boothbay Fund Management
New York
$510K -$214K -22,390 -30%
MCM
33
Moore Capital Management
New York
$493K – – –
PNC Financial Services Group
34
PNC Financial Services Group
Pennsylvania
$451K +$326K +34,022 +291%
Northern Trust
35
Northern Trust
Illinois
$371K +$129K +13,434 +56%
JP Morgan Chase
36
JP Morgan Chase
New York
$332K -$601K -62,810 -65%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$321K -$43.1K -4,500 -12%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$303K -$238K -24,866 -45%
FPC
39
Falcon Point Capital
California
$252K +$245K +25,608 New
NSEDCP
40
NJ State Employees Deferred Compensation Plan
New Jersey
$247K – – –
State Street
41
State Street
Massachusetts
$204K – – –
Geode Capital Management
42
Geode Capital Management
Massachusetts
$189K +$49.4K +5,158 +37%
EWM
43
Elmwood Wealth Management
California
$185K – – –
CS
44
Credit Suisse
Switzerland
$143K +$139K +14,512 New
Invesco
45
Invesco
Georgia
$137K +$133K +13,858 New
Dimensional Fund Advisors
46
Dimensional Fund Advisors
Texas
$110K – – –
Bank of Montreal
47
Bank of Montreal
Ontario, Canada
$106K – – –
ARTA
48
A.R.T. Advisors
New York
$106K +$103K +10,760 New
AC
49
Athanor Capital
New York
$100K +$96.6K +10,100 New
IVM
50
InterWest Venture Management
California
$82K – – –
1
2
3

XENE Hedge Fund Activity: Q2 2019 in Review

60 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2019, worth a combined $173M — down 3.9% from $180M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of XENE and 8 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 18 added.

The largest buyer was Eventide Asset Management, adding an estimated $6.25M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.42M sold.

  • 60 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2019, down from 63 in Q1 2019.
  • Funds reported $173M of Xenon Pharmaceuticals stock for Q2 2019, down 3.9% quarter-over-quarter.
  • 8 funds opened new Xenon Pharmaceuticals positions in Q2 2019 and 10 closed out, a net change of -2 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2019 was Eventide Asset Management, an estimated $6.25M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2019 was Sphera Funds Management, an estimated $5.42M sold.

Based on aggregated 13F filings for Q2 2019.